Subcutaneous glucose monitoring with GlucoDay®: comparison of the results to those obtained with the Endocrine Artificial Pancreas

• Published in: Hormones (Athens, Greece) Vol. 9; no. 2; pp. 145 - 150
• Main Authors: Dimitriadis, George, Boutati, Eleni, Raptis, Athanasios E., Hatziagelaki, Erifili, Mitrou, Panayota, Lambadiari, Vaia, Tountas, Nikolaos, Economopoulos, Theofanis, Raptis, Sotirios A.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-04-2010
• Subjects: Adult; Blood Glucose - metabolism; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - diagnosis; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Endocrinology; Equipment Design; Hexokinase - metabolism; Humans; Medicine; Medicine & Public Health; Metabolic Diseases; Middle Aged; Monitoring, Ambulatory - instrumentation; Pancreas, Artificial; Predictive Value of Tests; Regression Analysis; Reproducibility of Results; Research Paper; Subcutaneous Tissue - metabolism; Glucose monitoring; GlucoDay; Artificial Pancreas; Diabetes; Subcutaneous tissue
• DOI: 10.14310/horm.2002.1264
• EISSN: 2520-8721
• ISSN: 1109-3099

OBJECTIVE: This study was undertaken to assess the accuracy of GlucoDay® — a portable detector of subcutaneous glucose — by comparing the results to those obtained by Biostator® an established and reliable method for continuous glucose measurement in whole blood. DESIGN: Subjects with type 1 diabetes (n:6), subjects with type 2 diabetes (n:6), and six healthy controls were studied for 24 hours; they consumed three main meals. The GlucoDay® was connected to the subjects by inserting a microfibre probe into the periumbilical subcutaneous area, whilst the Biostator® was inserted by a double-lumen catheter into an antecubital vein. A third catheter was inserted into a separate vein for blood withdrawal to measure glucose by the hexokinase method. RESULTS: The three methods (GlucoDay®-Biostator®-hexokinase) were equally accurate in measuring glucose levels (p=0.233, Kruskall-Wallis test). The glucose measurements performed with GlucoDay® and Biostator® were significantly correlated with those performed with hexokinase (p<0.001, r2=66.65% and p<0.001, r2=64.4%, respectively, using simple regression analysis). CONCLUSIONS: Measurements of glucose fluctuations in the subcutaneous tissue with the GlucoDay® were close to those in blood determined by the Biostator®. GlucoDay® is therefore a reliable method for continuous glucose monitoring and may prove useful for optimizating treatment in patients with type 1 or type 2 diabetes.